SCHEMBL6285807

SCHEMBL6285807

CC(C(=O)NS(=O)(=O)CCNC(=O)OCc1ccccc1)c1ccc(C(=O)c2ccccc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.47
MAOA P21397 1/20 0.47
ADRA1A P35348 1/20 0.47
DRD3 P35462 1/20 0.47
KCNH2 Q12809 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTT P42858 1/20 0.39
MMP2 P08253 2/20 0.38
MMP3 P08254 2/20 0.38
MMP9 P14780 2/20 0.38
MMP14 P50281 2/20 0.38
CTSK P43235 1/20 0.38
MMP1 P03956 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7128316 0.87 ADRA2C (0.49) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL6332320 0.81 GLI1 (0.53) CYP1A2CYP3A4CYP2D6CYP2C9HPGD
SCHEMBL6284421 0.80 HPGD (0.57) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL27568093 0.77 HPGD (0.44) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL12608953 0.77 HPGD (0.59) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL6320504 0.76 CXCR1 (0.53) LMNASMN1; SMN2CA2MAPTCA1
SCHEMBL6286862 0.75 CA2 (0.39) LMNASMN1; SMN2HTTMMP2MMP3
SCHEMBL6328423 0.74 GLI1 (0.52) CYP2D6LMNASMN1; SMN2HTTMMP2
SCHEMBL6284426 0.72 HPGD (0.61) ADRA2CMAOAADRA1ADRD3KCNH2
SCHEMBL4069328 0.69 LMNA (0.53) LMNASMN1; SMN2HTTL3MBTL1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 ADRA2C 1739/4885MAOA 3259/4885ADRA1A 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.